Nanomedicine: current status and future prospects

被引:1365
作者
Moghimi, SM [1 ]
Hunter, AC
Murray, JC
机构
[1] Univ Brighton, Sch Pharm, Mol Targeting & Polymer Toxicol Grp, Brighton BN2 4GJ, E Sussex, England
[2] Univ Hosp, Wolfson Digest Dis Ctr, Canc Res UK, Tumour Cytokine Biol Grp, Nottingham, England
关键词
nanotechnology; nanosized drug delivery systems; nanoparticles; medical imaging; gene therapy; nanofibers; macrophage; endothelium; intracellular delivery; extravasation; toxicity;
D O I
10.1096/fj.04-2747rev
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Applications of nanotechnology for treatment, diagnosis, monitoring, and control of biological systems has recently been referred to as "nanomedicine" by the National Institutes of Health. Research into the rational delivery and targeting of pharmaceutical, therapeutic, and diagnostic agents is at the forefront of projects in nanomedicine. These involve the identification of precise targets (cells and receptors) related to specific clinical conditions and choice of the appropriate nanocarriers to achieve the required responses while minimizing the side effects. Mononuclear phagocytes, dendritic cells, endothelial cells, and cancers (tumor cells, as well as tumor neovasculature) are key targets. Today, nanotechnology and nanoscience approaches to particle design and formulation are beginning to expand the market for many drugs and are forming the basis for a highly profitable niche within the industry, but some predicted benefits are hyped. This article will highlight rational approaches in design and surface engineering of nanoscale vehicles and entities for site-specific drug delivery and medical imaging after parenteral administration. Potential pitfalls or side effects associated with nanoparticles are also discussed.
引用
收藏
页码:311 / 330
页数:20
相关论文
共 163 条
[61]   Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function [J].
Jain, RK .
JOURNAL OF CONTROLLED RELEASE, 2001, 74 (1-3) :7-25
[62]   Long-term multiple color imaging of live cells using quantum dot bioconjugates [J].
Jaiswal, JK ;
Mattoussi, H ;
Mauro, JM ;
Simon, SM .
NATURE BIOTECHNOLOGY, 2003, 21 (01) :47-51
[63]   PDMAEMA is internalised by endocytosis but does not physically disrupt endosomes [J].
Jones, RA ;
Poniris, MH ;
Wilson, MR .
JOURNAL OF CONTROLLED RELEASE, 2004, 96 (03) :379-391
[64]   Biophysical mechanisms of phospholipase A2 activation and their use in liposome-based drug delivery [J].
Jorgensen, K ;
Davidsen, J ;
Mouritsen, OG .
FEBS LETTERS, 2002, 531 (01) :23-27
[65]   An essential relationship between ATP depletion and chemosensitizing activity of Pluronic® block copolymers [J].
Kabanov, AV ;
Batrakova, EV ;
Alakhov, VY .
JOURNAL OF CONTROLLED RELEASE, 2003, 91 (1-2) :75-83
[66]   Gene transfer with modified polyethylenimines [J].
Kichler, A .
JOURNAL OF GENE MEDICINE, 2004, 6 :S3-S10
[67]   Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin [J].
Kim, S ;
Bell, K ;
Mousa, SA ;
Varner, JA .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (04) :1345-1362
[68]   Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping [J].
Kim, S ;
Lim, YT ;
Soltesz, EG ;
De Grand, AM ;
Lee, J ;
Nakayama, A ;
Parker, JA ;
Mihaljevic, T ;
Laurence, RG ;
Dor, DM ;
Cohn, LH ;
Bawendi, MG ;
Frangioni, JV .
NATURE BIOTECHNOLOGY, 2004, 22 (01) :93-97
[69]   Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs [J].
King, M ;
Su, W ;
Chang, A ;
Zuckerman, A ;
Pasternak, GW .
NATURE NEUROSCIENCE, 2001, 4 (03) :268-274
[70]   Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging [J].
Kooi, ME ;
Cappendijk, VC ;
Cleutjens, KBJM ;
Kessels, AGH ;
Kitslaar, PJEHM ;
Borgers, M ;
Frederik, PM ;
Daemen, MJAP ;
van Engelshoven, JMA .
CIRCULATION, 2003, 107 (19) :2453-2458